Research Topics
| G C FarrellSummaryAffiliation: University of Washington Country: USA Publications
| Collaborators
|
Detail Information
Publications
Nonalcoholic fatty liver disease: from steatosis to cirrhosisGeoffrey C Farrell
The Storr Liver Unit, Westmead s Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
Hepatology 43:S99-S112. 2006..Future challenges are to approach NAFLD as a preventive public health initiative and to motivate affected persons to adopt a healthier lifestyle...- Management of chronic hepatitis B virus infection: a new era of disease controlG C Farrell
Department of Gastroenterology and Hepatology, The Canberra Hospital and Department of Medicine, Australian National University, Canberra, Australian Capital Territory, Australia
Intern Med J 36:100-13. 2006..Further improvements in treatment of CHB are needed to prevent drug resistance and permanently suppress viral replication by eradicating viral templates or stimulating host immune responsiveness to HBV... - Drug-induced hepatic injuryG C Farrell
Storr Liver Unit, University of Sydney at Westmead Hospital, NSW, Australia
J Gastroenterol Hepatol 12:S242-50. 1997..Minocycline and diclofenac will be mentioned as two drugs for which drug hepatitis is an exceedingly rare complication. Finally, the evidence that Chinese herbal medicines can be hepatotoxic will be reviewed... - Clinical potential of emerging new agents in hepatitis BG C Farrell
Department of Medicine, University of Sydney at Westmead Hospital, New South Wales, Australia
Drugs 60:701-10. 2000.... - Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]Jason M Hui
Storr Liver Unit, Westmead Millennium Insitute, and Department of Gastroenterology and Hepatology, University of Sydney at Westmead Hospital, New South Wales, Australia
Gastroenterology 125:1695-704. 2003..Further, our findings support the hypothesis that insulin resistance may contribute to fibrotic progression in chronic hepatitis C virus infection... - Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis CDinesh Kumar
Storr Liver Unit, Westmead Millennium Institute, Westmead, New South Wales, Australia
J Gastroenterol Hepatol 20:1395-400. 2005..CONCLUSIONS: Hepatic steatosis does not augment the risk of hepatocarcinogenesis in patients with chronic HCV infection... - Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?Claire Z Larter
The Storr Liver Unit, Westmead s Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia
J Hepatol 44:253-61. 2006 - How should we manage patients with non-alcoholic fatty liver disease in 2007?Henry L Y Chan
Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
J Gastroenterol Hepatol 22:801-8. 2007..Lifestyle changes are the first line and mainstay of management... - The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLDPaul Angulo
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Hepatology 45:846-54. 2007..CONCLUSION: a simple scoring system accurately separates patients with NAFLD with and without advanced fibrosis, rendering liver biopsy for identification of advanced fibrosis unnecessary in a substantial proportion of patients... - Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summaryGeoffrey C Farrell
Gastroenterology and Hepatology Unit, The Canberra Hospital, Canberra, Australian Capital Territory, Garran, Australia
J Gastroenterol Hepatol 22:775-7. 2007 - Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelinesShivakumar Chitturi
Gastroenterology and Hepatology Unit, The Canberra Hospital, Canberra, Australian Capital Territory, Garran, Australia
J Gastroenterol Hepatol 22:778-87. 2007..The present document reviews the reasoning and evidence behind the APWP-NAFLD proposals for definition, assessment, and management of NAFLD in the Asia-Pacific region... - Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokinesIan Homer Y Cua
Storr Liver Unit, Westmead Millennium Institute and Department of Gastroenterology and Hepatology, University of Sydney at Westmead Hospital, Westmead, New South Wales, Australia
Hepatology 46:66-73. 2007..HCV-associated IR is most likely an adipocytokine-independent effect of the virus to modulate insulin sensitivity... - Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis CJason M Hui
Storr Liver Unit, Westmead Millennium Institute, and Department of Gastroenterology and Hepatology, Westmead Hospital, University of Sydney, NSW, Australia
Hepatology 38:420-7. 2003..In conclusion, liver failure is the main cause of morbidity and mortality in NASH-associated cirrhosis. The prognosis is either similar or less severe than HCV-cirrhosis, except that HCC appears less common... - Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progressionShirley A Coverdale
The Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, NSW, Australia
Am J Gastroenterol 98:1384-90. 2003..Both could be used to reliably identify those who do not have fibrotic progression, and platelet count also has a high positive predictive value for disease progression... - Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic responseDinesh Kumar
Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Australia
Hepatology 36:1266-72. 2002..7-481, P =.007). In conclusion, these data provide strong support for a direct causal association between HCV genotype 3 infection and hepatic steatosis... - HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severityShivakumar Chitturi
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, New South Wales 2145, Australia
Hepatology 36:142-9. 2002..In conclusion, hepatic iron is not a factor linked to hepatic fibrogenesis in patients with NASH. HFE mutations do not confer an additional risk of hepatic fibrosis in this disorder... - Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in miceEmilia Ip
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, Australia
Hepatology 38:123-32. 2003.... - COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediatorJun Yu
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, Australia
Hepatology 43:826-36. 2006..COX-2 may therefore be a pro-inflammatory mediator in metabolic forms of steatohepatitis... - NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitisAileen Dela Pena
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, NSW, Australia
J Hepatol 46:304-13. 2007..g., gp91phox) renders NADPH oxidase inactive. We tested whether activated inflammatory cells contribute to oxidant stress in steatohepatitis... - Drugs and steatohepatitisGeoffrey C Farrell
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
Semin Liver Dis 22:185-94. 2002..It follows that early recognition of hepatotoxicity is crucial to prevent the development of severer forms of liver disease and improve the clinical outcome... - New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infectionGeoffrey C Farrell
J Gastroenterol Hepatol 22:607-10. 2007 - TNF-alpha as therapeutic target in NASH: tried, but not yet provenShivakumar Chitturi
J Gastroenterol Hepatol 22:613-4. 2007 - Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistanceJason M Hui
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, New South Wales, Australia
Am J Gastroenterol 97:1003-9. 2002.... - Liver regeneration in obese mice with fatty livers: does the impairment have relevance for other types of fatty liver disease?Geoffrey C Farrell
Hepatology 35:731-2. 2002 - Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitisJun Yu
Institute of Digestive Disease, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
Biochem Biophys Res Commun 356:53-9. 2007..These findings indicate that NO-1886 is a potential therapeutic agent for steatohepatitis... - NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndromeShivakumar Chitturi
Storr Liver Unit, Westmead Millennium Institute, University of Sydney, New South Wales, Australia
Hepatology 35:373-9. 2002..IR is present in mild as well as advanced cases of NASH but is unusual in chronic HCV of similar fibrotic severity... - Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic healthShivakumar Chitturi
J Gastroenterol Hepatol 22:967-9. 2007 - Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulationClaire Z Larter
Australian National University Medical School at The Canberra Hospital, Canberra, Australian Capital Territory, Australia
J Gastroenterol Hepatol 23:267-75. 2008..n-3 polyunsaturated fatty acids (PUFA), such as those found in fish oil (FO), are naturally occurring PPARalpha ligands which also suppress lipid synthesis... 
Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathwaysClaire Z Larter
Department of Gastroenterology and Hepatology, ANU Medical School, Australian National University at The Canberra Hospital, ACT, Australia
J Hepatol 48:638-47. 2008..We determined the effects of dietary lipid composition on steatohepatitis development with particular attention to the nature of lipid molecules that accumulate in the liver and pathways of hepatic triglyceride synthesis...- Hepatotoxic slimming aids and other herbal hepatotoxinsShivakumar Chitturi
Gastroenterology and Hepatology Unit, The Canberra Hospital, Canberra, Australian Capital Territory, Australia
J Gastroenterol Hepatol 23:366-73. 2008.... - Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant miceTodor Arsov
John Curtin School of Medical Research, The Australian National University ANU, Canberra, ACT, Australia
Biochem Biophys Res Commun 342:1152-9. 2006..In this model of metabolic syndrome, transition of steatosis to steatohepatitis was associated with hypoadiponectinemia, a mediator of hepatic fatty acid disposal pathways... - Leptin is essential for the hepatic fibrogenic response to chronic liver injuryIsabelle A Leclercq
Storr Liver Unit, Department of Medicine and Westmead Millennium Institute, University of Sydney at Westmead Hospital, NSW 2145, Australia
J Hepatol 37:206-13. 2002..The correlation between increased leptin, obesity and hepatic fibrosis prompted us to hypothesise that leptin has profibrogenic effects on the liver... - Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in miceRobert S McCuskey
Department of Cell Biology and Anatomy, College of Medicine, University of Arizona, Tucson, AZ 85724 5044, USA
Hepatology 40:386-93. 2004..In conclusion, these results are consistent with a dysfunctional hepatic microvasculature. Thus, microvascular changes may contribute to progressive liver injury in metabolic and toxic forms of steatohepatitis... - Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injuryIsabelle A Leclercq
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, NSW, Australia
Gastroenterology 124:1451-64. 2003..Our aim was to establish whether defective liver regeneration in ob/ob mice is a direct consequence of leptin-dependent, intracellular signaling mechanisms controlling cell-cycle regulation in hepatocytes... - Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about themJason M Hui
J Gastroenterol Hepatol 18:1115-7. 2003 - Pharmacotherapy of hepatocellular carcinomaJohn F Perry
AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Missenden Rd, Camperdown 2050, Australia
Expert Opin Pharmacother 4:2175-85. 2003..This review summarises some of the therapeutic modalities used for HCC, with an emphasis on pharmacological therapies... - Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic settingDinesh Kumar
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
Med J Aust 178:267-71. 2003..Dose reduction was required in 18% of patients. CONCLUSIONS: In a hospital clinic setting the effectiveness of interferon alfa-2b/ribavirin combination therapy appears equivalent to published results from clinical trials... - Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?Shivakumar Chitturi
Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
J Gastroenterol Hepatol 19:368-74. 2004..Pharmacotherapy may play a role in selected individuals. A regional agenda for case definition, future study and public health initiatives is urgently required... - Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up studyShirley A Coverdale
Storr Liver Unit, Westmead Millennium Institute and University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia
Am J Gastroenterol 99:636-44. 2004..However, in the absence of an antiviral treatment response, a course of interferon does not reduce risks of liver cancer or liver failure... - Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability indexArchana Sud
Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead, New South Wales, Australia
Hepatology 39:1239-47. 2004..Such an index should prove useful to guide decision making regarding the need for liver biopsy, and potentially for avoiding or deferring biopsy in a large proportion of patients with mild liver disease... - High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLDJason M Hui
Hepatology 39:1458-9. 2004 - Beyond insulin resistance in NASH: TNF-alpha or adiponectin?Jason M Hui
Storr Liver Unit, Westmead Millennium Institute, University of Sydney, and Department of Gastroenterology and Hepatology, Westmead Hospital, NSW, Australia
Hepatology 40:46-54. 2004..Reduced adiponectin level is associated with more extensive necroinflammation and may contribute to the development of necroinflammatory forms of NAFLD... - Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?Geoffrey C Farrell
Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, New South Wales, Australia
J Gastroenterol Hepatol 18:124-38. 2003..Some emerging concepts on pathogenesis will be mentioned briefly, but the emphasis will be on the potency of lifestyle adjustments (physical activity and diet) to prevent or reverse fatty liver disorders... - Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in miceIsabelle A Leclercq
Gastroenterology Unit, Universite Catholique de Louvain UCL, GAEN UCL 53 79, avenue E Mounier, 53, B 1200 Brussels, Belgium
J Hepatol 41:926-34. 2004..We analysed the role of NF-kappaB redox-sensitive signalling pathway of inflammatory recruitment in experimental steatohepatitis... - Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis CPriyanka Bandara
Storr Liver Unit, Westmead Millennium Institute, Sydney, Australia
Liver Int 25:518-26. 2005..Controlled intervention studies with vitamin C and agents that boost endogenous GSH levels are warranted... - Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infectionJason M Hui
Storr Liver Unit, Westmead Millennium Institute, University of Sydney and Department of Anatomical Pathology, New South Wales, Australia
J Gastroenterol Hepatol 17:873-81. 2002..Although steatosis and BMI were not associated with hepatic fibrosis, their relationship with serum insulin suggests that metabolic factors related to insulin action could influence fibrogenesis in hepatitis C... - Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivoJun Yu
Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia
Hepatology 43:134-43. 2006..PPARgamma therefore represents a putative molecular target for chemopreventive therapy or inhibition of liver cancer growth... - VAT fat is bad for the liver, SAT fat is not!Jian-Gao Fan
J Gastroenterol Hepatol 23:829-32. 2008